Research programme: neurological disorders therapeutics - Prevacus

Drug Profile

Research programme: neurological disorders therapeutics - Prevacus

Alternative Names: PRV-002; Synthetic neurosteroids - Prevacus

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prevacus
  • Class Anti-inflammatories; Steroids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Neurological disorders

Most Recent Events

  • 18 May 2018 Prevacus enters into an agreement with BrainScope to use its BrainScope One device for a clinical trial in Concussion
  • 18 May 2018 Prevacus plans a phase Ib trial for PRV 002 for Concussion
  • 09 Jan 2015 Preclinical trials in Brain injuries in USA (Intranasal) prior to January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top